Navidea Appoints Jed Latkin as Interim Chief Operating Officer
April 26 2016 - 4:00PM
Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), announced
today that Jed A. Latkin has been appointed interim Chief Operating
Officer effective April 20, 2016. Jed has more than 20 years of
experience in the financial industry supporting many investments in
major markets including biotechnology and pharmaceuticals by
providing executive direction and preserving operational control
during transitional periods.
“It is with great pleasure that Navidea welcomes Jed Latkin as
interim Chief Operating Officer,” said Michael Goldberg, M.D.,
Chairman of the Board of Navidea. “Jed is a seasoned financial
executive with an excellent history of achievement. His proven
track record of success will be valuable to the Company’s
day-to-day operations.”
“I am delighted to join the Navidea team and am committed to
supporting attainment of our corporate goals which will expand the
Company’s growth and drive shareholder value," commented Jed
Latkin. “I look forward to the challenge at this important time in
the Company’s evolution.”
Jed Latkin was employed by Nagel Avenue Capital, LLC since 2010
and in that capacity he provided contracted services as a Portfolio
Manager, Asset Based Lending for Platinum Partners Value Arbitrage
Fund L.P. Jed has been responsible for a large diversified
portfolio of asset based investments in varying industries
including product manufacturing, agriculture, energy, and
healthcare. In connection with this role, he has served as CFO of
Viper Powersports, Inc., CEO of End of Life Petroleum Holdings,
LLC, CEO of Black Elk Energy, LLC, Portfolio Manager of Precious
Capital, LLC and CFO of West Ventures, LLC. Prior to his position
at Nagel Avenue Capital, LLC he was a Senior Research Analyst,
Global Markets for ING Investment Management and held various
finance roles at Troika Dialog, Morgan Stanley, Fleet Boston
Robertson Stephens and Citicorp Securities. Jed served on the Board
of Directors for Viper Powersports, Inc. from 2012 to 2013. He
currently serves on the boards of the Renewable Fuels Association
and Buffalo Lake Advanced Biofuels. Jed has a BA from Rutgers
University and an MBA from Columbia Business School.
In connection with his appointment, Navidea intends to enter
into an employment agreement with Mr. Latkin. The Company also
granted options to purchase 45,000 shares of Navidea’s common stock
at an exercise price of $1.50 per share. The options vest and
become exercisable in six equal monthly tranches, subject to Mr.
Latkin’s continued employment by Navidea.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision immunodiagnostic agents and
immunotherapeutics. Navidea is developing multiple
precision-targeted products and platforms including Manocept™ and
NAV4694 to help identify the sites and pathways of undetected
disease and enable better diagnostic accuracy, clinical
decision-making, targeted treatment and, ultimately, patient care.
Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s
first commercial product from the Manocept platform, was approved
by the FDA in March 2013 and in Europe in November 2014. The
development activities of the Manocept immunotherapeutic platform
will be conducted by Navidea in conjunction with its subsidiary,
Macrophage Therapeutics. Navidea’s strategy is to deliver superior
growth and shareholder return by bringing to market novel products
and advancing the Company’s pipeline through global partnering and
commercialization efforts. For more information, please visit
www.navidea.com.
The Private Securities Litigation Reform Act of 1995 (the Act)
provides a safe harbor for forward-looking statements made by or on
behalf of the Company. Statements in this news release, which
relate to other than strictly historical facts, such as statements
about the Company’s plans and strategies, expectations for future
financial performance, new and existing products and technologies,
anticipated clinical and regulatory pathways, and markets for the
Company’s products are forward-looking statements within the
meaning of the Act. The words “believe,” “expect,” “anticipate,”
“estimate,” “project,” and similar expressions identify
forward-looking statements that speak only as of the date hereof.
Investors are cautioned that such statements involve risks and
uncertainties that could cause actual results to differ materially
from historical or anticipated results due to many factors
including, but not limited to, the Company’s continuing operating
losses, uncertainty of market acceptance of its products, reliance
on third party manufacturers, accumulated deficit, future capital
needs, uncertainty of capital funding, dependence on limited
product line and distribution channels, competition, limited
marketing and manufacturing experience, risks of development of new
products, regulatory risks and other risks detailed in the
Company’s most recent Annual Report on Form 10-K and other
Securities and Exchange Commission filings. The Company undertakes
no obligation to publicly update or revise any forward-looking
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160426006896/en/
Navidea Biopharmaceuticals, Inc.Investors & MediaSharon
Correia, 978-655-2686Senior Director, Corporate Communications
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2024 to May 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From May 2023 to May 2024